Filing Flows

Filing Flows › 8-K events › Amgen

Amgen: departure or appointment of directors and officers

Form 8-K filed Oct 27, 2026 · items 5.02

CEO changesAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS

What the filing says

On October 26, 2026, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed David W. Gibbs as a director of the Company, effective immediately.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Amgen at a glance

Latest quarterQ3 2026
Revenue$10.4B
Revenue Y/Y+8%
Operating margin35.8%
IndustryBiological Products, (No Diagnostic Substances)

Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%. The chart follows the revenue to costs, profit and cash.

Amgen: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.